Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Medtronic
Chubb
Novartis
Daiichi Sankyo
Cerilliant
Covington
McKinsey
Chinese Patent Office

Generated: October 17, 2017

DrugPatentWatch Database Preview

Parke Davis Company Profile

« Back to Dashboard

What is the competitive landscape for PARKE DAVIS, and what generic alternatives to PARKE DAVIS drugs are available?

PARKE DAVIS has one hundred and four approved drugs.

There are two US patents protecting PARKE DAVIS drugs.

Summary for Applicant: Parke Davis

US Patents:2
Tradenames:77
Ingredients:68
NDAs:104
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parke Davis
POVAN
pyrvinium pamoate
SUSPENSION;ORAL011964-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
MEPROBAMATE
meprobamate
TABLET;ORAL084744-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
NORLESTRIN FE 2.5/50
ethinyl estradiol; ferrous fumarate; norethindrone acetate
TABLET;ORAL-28016854-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
INDOMETHACIN
indomethacin
CAPSULE;ORAL018806-002Nov 23, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
ISOPROTERENOL HYDROCHLORIDE
isoproterenol hydrochloride
SOLUTION;INHALATION085994-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
PENAPAR-VK
penicillin v potassium
TABLET;ORAL062001-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
PROLOID
thyroglobulin
TABLET;ORAL002245-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
NARDIL
phenelzine sulfate
TABLET;ORAL011909-002Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Parke Davis
METHYLDOPA
methyldopa
TABLET;ORAL070331-001Apr 15, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Parke Davis
ERYTHROMYCIN ETHYLSUCCINATE
erythromycin ethylsuccinate
SUSPENSION;ORAL062231-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Parke Davis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parke Davis
NEURONTIN
gabapentin
SOLUTION;ORAL021129-001Mar 2, 2000► Subscribe► Subscribe
Parke Davis
FEMPATCH
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020417-001Dec 3, 1996► Subscribe► Subscribe
Parke Davis
CHOLYBAR
cholestyramine
BAR, CHEWABLE;ORAL071739-001May 26, 1988► Subscribe► Subscribe
Parke Davis
CEREBYX
fosphenytoin sodium
INJECTABLE;INJECTION020450-001Aug 5, 1996► Subscribe► Subscribe
Parke Davis
CHOLYBAR
cholestyramine
BAR, CHEWABLE;ORAL071621-001May 26, 1988► Subscribe► Subscribe
Parke Davis
NEURONTIN
gabapentin
SOLUTION;ORAL021129-001Mar 2, 2000► Subscribe► Subscribe
Parke Davis
FEMPATCH
estradiol
FILM, EXTENDED RELEASE;TRANSDERMAL020417-001Dec 3, 1996► Subscribe► Subscribe
Parke Davis
CEREBYX
fosphenytoin sodium
INJECTABLE;INJECTION020450-001Aug 5, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PARKE DAVIS drugs

Drugname Dosage Strength Tradename Submissiondate
nitroglycerin
Sublingual Tablets0.6 mg
NITROSTAT
12/29/2011
nitroglycerin
Sublingual Tablets0.3 mg, 0.4 mg and 0.6 mg
NITROSTAT
10/19/2005

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
Deloitte
UBS
Queensland Health
Julphar
Express Scripts
AstraZeneca
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot